Tour the labs
Services provided at this site
Our Cambridge facility is located 50 miles north of London in the UK
Our Cambridge site has relocated to larger premises and now houses multiple modern preclinical research laboratories providing a wide range of early derisking services.
Our Early Development Services team focuses on a full risk assessment platform for in silico and in vitro services for developability, immunogenicity, stability, antibody humanization, protein engineering and provide non-GMP mammalian and microbial expression services.
Our protein experts can help optimize your drug candidate to give you the best chance for clinical success.
Non-GMP protein expression and product characterization
- Mammalian cell culture (CHO cell lines)
- E.coli expression
- Pichia expression
- Expression quantities from mL to 20L/mg-5g
- Affinity and non-affinity chromatography
- Protein characterization
- Binding affinity analysis
In silico assessment and protein engineering
- Computational analysis of protein sequence and structure
- Antibody humanization and deimmunization
- T cell Immunogenicity risk profiling using proprietary Epibase® platform
- Protein engineering to de-risk development and manufacture
- Aggregation prediction using proprietary Sentinel APART® platform
- Manufacturability assessment
Technologies available at this site
Sustainability